Seroprevalence of low rubella IgG antibody levels among antenatal women in England tested by NHS Blood and Transplant: 2004–2009. Is rubella susceptibility increasing?

Vaccine ◽  
2012 ◽  
Vol 30 (2) ◽  
pp. 161-167 ◽  
Author(s):  
Lisa Byrne ◽  
Lisa Brant ◽  
Claire Reynolds ◽  
Mary Ramsay
Keyword(s):  
Igg Antibody ◽  
Antibody Levels

scholarly journals Structural Insight into CVB3-VLP Non-Adjuvanted Vaccine

2020 ◽  
Vol 8 (9) ◽  
pp. 1287
Author(s):  
Minna M. Hankaniemi ◽  
Mo A. Baikoghli ◽  
Virginia M. Stone ◽  
Li Xing ◽  
Outi Väätäinen ◽  
...  
Keyword(s):  
Exchange Chromatography ◽  
Scale Production ◽  
Igg Antibody ◽  
Purification Method ◽  
Microscopy Imaging ◽  
Single Particle Reconstruction ◽  
Enhanced Production ◽  
Chronic Myocarditis ◽  
Flow Filtration ◽  
Antibody Levels

Coxsackievirus B (CVB) enteroviruses are common pathogens that can cause acute and chronic myocarditis, dilated cardiomyopathy, aseptic meningitis, and they are hypothesized to be a causal factor in type 1 diabetes. The licensed enterovirus vaccines and those currently in clinical development are traditional inactivated or live attenuated vaccines. Even though these vaccines work well in the prevention of enterovirus diseases, new vaccine technologies, like virus-like particles (VLPs), can offer important advantages in the manufacturing and epitope engineering. We have previously produced VLPs for CVB3 and CVB1 in insect cells. Here, we describe the production of CVB3-VLPs with enhanced production yield and purity using an improved purification method consisting of tangential flow filtration and ion exchange chromatography, which is compatible with industrial scale production. We also resolved the CVB3-VLP structure by Cryo-Electron Microscopy imaging and single particle reconstruction. The VLP diameter is 30.9 nm on average, and it is similar to Coxsackievirus A VLPs and the expanded enterovirus cell-entry intermediate (the 135s particle), which is ~2 nm larger than the mature virion. High neutralizing and total IgG antibody levels, the latter being a predominantly Th2 type (IgG1) phenotype, were detected in C57BL/6J mice immunized with non-adjuvanted CVB3-VLP vaccine. The structural and immunogenic data presented here indicate the potential of this improved methodology to produce highly immunogenic enterovirus VLP-vaccines in the future.

Measurement of Specific IgG Antibody Levels in Serum of Patients on Regimes Comprising High Total Dose Beta-Lactam Therapy

1986 ◽  
Vol 79 (4) ◽  
pp. 344-348 ◽  
Author(s):  
D. Lee ◽  
Janet M. Dewdney ◽  
R.G. Edwards ◽  
K.A. Neftel ◽  
M. Wälti
Keyword(s):  
Total Dose ◽  
Beta Lactam ◽  
Igg Antibody ◽  
Specific Igg ◽  
Antibody Levels ◽  
High Total Dose

scholarly journals Antibody level of New Zealand children immunized with the triple vaccine DTP (diphtheria-tetanus-pertussis)

1988 ◽  
Vol 101 (2) ◽  
pp. 405-410 ◽  
Author(s):  
R. C. H Lau
Keyword(s):  
New Zealand ◽  
Immunosorbent Assay ◽  
Antibody Level ◽  
Herd Immunity ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibody ◽  
Immunization Strategy ◽  
The Mean ◽  
Antibody Levels

SUMMARYEnzyme-linked immunosorbent assay (ELISA) tests were used to measure IgG antibody levels in 2638 New Zealand children who had been immunized with the triple vaccine DTP. The percentage of children immune to diphtheria decreased with age. The percentage of children immune to tetanus varied from 67.1 to 55.0%. The percentage of children with measurable antibody to pertussis increased with age. The mean percentages of children with measurable antibody or immunity to one or more DTP components were 34.2% (with 3 components), 34.4% (2 components), and 78.1% (1 component). It appears the immunization strategy for diphtheria and tetanus is satisfactory for herd immunity in New Zealand children. However, the current pertussis strategy may not be providing adequate immunity to 5-year-olds in this country.

scholarly journals Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines

Vaccines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 99
Author(s):  
Joanna Szczepanek ◽  
Monika Skorupa ◽  
Agnieszka Goroncy ◽  
Joanna Jarkiewicz-Tretyn ◽  
Aleksandra Wypych ◽  
...  
Keyword(s):  
Cellular Response ◽  
Protein A ◽  
Humoral Response ◽  
Blood Type ◽  
Vaccine Response ◽  
Serum Samples ◽  
Igg Antibody ◽  
Three Samples ◽  
Nicolaus Copernicus ◽  
Antibody Levels

Background: COVID-19 vaccines induce a differentiated humoral and cellular response, and one of the comparable parameters of the vaccine response is the determination of IgG antibodies. Materials and Methods: Concentrations of IgG anti-SARS-CoV-2 antibodies were analyzed at three time points (at the beginning of May, at the end of June and at the end of September). Serum samples were obtained from 954 employees of the Nicolaus Copernicus University in Toruń (a total of three samples each were obtained from 511 vaccinated participants). IgG antibody concentrations were determined by enzyme immunoassay. The statistical analysis included comparisons between vaccines, between convalescents and COVID-19 non-patients, between individual measurements and included the gender, age and blood groups of participants. Results: There were significant differences in antibody levels between mRNA and vector vaccines. People vaccinated with mRNA-1273 achieved the highest levels of antibodies, regardless of the time since full vaccination. People vaccinated with ChAdOx1 nCoV-2019 produced several times lower antibody levels compared to the mRNA vaccines, while the antibody levels were more stable. In the case of each of the vaccines, the factor having the strongest impact on the level and stability of the IgG antibody titers was previous SARS-CoV-2 infection. There were no significant correlations with age, gender and blood type. Summary: mRNA vaccines induce a stronger humoral response of the immune system with the fastest loss of antibodies over time.

The Role of Bacteroides Gingivalis in Periodontal Disease

1988 ◽  
Vol 2 (2) ◽  
pp. 260-268 ◽  
Author(s):  
K. Okuda ◽  
I. Takazoe
Keyword(s):  
Surface Antigens ◽  
Biological Properties ◽  
Igg Antibody ◽  
Cotton Threads ◽  
Bacteroides Gingivalis ◽  
Antibody Levels ◽  
Mandibular First Molar ◽  
Attachment Factor

The microbial flora in adult advanced periodontitis lesions is comprised of Gram-negative rods, with Bacteroides gingivalis as one of the major representatives. This review deals with biological properties of surface antigens, hemagglutinin (attachment factor), and capsular structure of B. gingivalis. Sera containing high IgG antibody levels to B. gingivalis enhanced the complement-mediated bactericidal activity in vitro, although the susceptibility to complement-mediated lysis differed among B. gingivalis strains. The protective effect of immunization against B. gingival is infection was examined in hamsters in which cotton threads had been tied to the gingival margins of the mandibular first molar. Repeated oral topical application of hyper-immune sera against B. gingivalis resulted in effective elimination of the organisms from the periodontal lesions in the experimental animals.

Human Immunoglobulins for Intravenous Use: Comparison of Available Preparations for Group B Streptococcal Antibody Levels, Opsonic Activity, and Efficacy in Animal Models

PEDIATRICS ◽  
1990 ◽  
Vol 86 (6) ◽  
pp. 955-962
Author(s):  
Laurence B. Givner
Keyword(s):  
Animal Models ◽  
Neonatal Sepsis ◽  
Protective Efficacy ◽  
Group B Streptococcus ◽  
Igg Antibody ◽  
Opsonic Activity ◽  
Immunoglobulin Preparations ◽  
Group B ◽  
Antibody Levels

Currently available human immunoglobulin preparations for intravenous use (IVIGs) are being used (with antibiotics) by some physicians for therapy of sepsis in newborns. Most neonatal sepsis and/or meningitis in this country is caused by group B Streptococcus (GBS), and most of these cases are due to type III GBS (III-GBS). The killing of III-GBS in vitro is dependent on specific IgG antibody. Adequate serum levels of specific III-GBS antibody protect the exposed newborn from the development of invasive disease. Therefore, III-GBS was used as a model to evaluate the activity of three IVIG preparations available for clinical use. Specific antibody levels, in vitro opsonophagocytic killing, and protective efficacy in animal models revealed differences in activity for III-GBS between the three IVIG preparations as well as between IVIG lots from the same manufacturer. Furthermore, it was found that the effect of IVIG using one of the assay methods may not reliably predict activity obtained using the other assays. These data document the inability to predict functional activity against a specific pathogen such as GBS on the part of a lot of IVIG chosen at random. In view of these findings and of the limited data evaluating clinical efficacy, IVIG cannot be recommended at this time for use in the therapy of infectious diseases such as neonatal sepsis.

IgG Levels after Treatment with Antigen Vials Based on the Scratch Testing, Intradermal Testing, Modified RAST Testing

1986 ◽  
Vol 95 (3_part_1) ◽  
pp. 307-311 ◽  
Author(s):  
Richard J. Trevino
Keyword(s):  
Scratch Testing ◽  
Igg Antibody ◽  
Intradermal Testing ◽  
Blocking Antibody ◽  
Multiple Treatment ◽  
End Point ◽  
Specific Igg ◽  
Inhalant Allergens ◽  
Inhalant Allergy ◽  
Antibody Levels

In this study, there were three groups of patients—each group consisting of four patients. The first group had been skin tested by the scratch method, the second group was skin tested by the end point titration intradermal method, and the third group had been tested for inhalant allergy by the modified RAST technique. All of them had multiple treatment vials made, dependent on the type of testing they had, and the vials all included the ten inhalants that were tested for. All patients had been treated for a year with weekly immunotherapy injections. Specific IgG levels, blocking antibody levels to the ten inhalant allergens, were determined. The results were that the patients who had been scratch tested had the lowest levels of specific IgG blocking antibody—while both intradermal end point titration and modified RAST testing had much higher elevations of blocking IgG antibody, with the RAST having the highest. It is concluded that, since the treatment vials prepared after scratch testing of all the antigens are at the same concentration, there are many antigens that are not given in adequate amounts to cause a good IgG response whereas, by calibrating the concentrations of antigens in the intradermal titration and the modified RAST testing, all the antigens are being injected in sufficient quantities to get a good blocking antibody response.

Sign in / Sign up

Export Citation Format

Share Document